An update on small molecule strategies targeting leishmaniasis

Area of Science:

• Parasitology
• Medicinal Chemistry
• Drug Discovery

Background:

• Leishmaniasis is a complex infectious disease caused by Leishmania parasites, transmitted by sandflies.
• Clinical manifestations include cutaneous, mucocutaneous, and visceral forms.
• Existing treatments like pentavalent antimonials and Amphotericin B are hampered by parasite resistance and diverse survival mechanisms.

Purpose of the Study:

• To provide an overview of leishmaniasis.
• To emphasize recent advancements in novel heterocyclic compounds with anti-leishmanial activity.
• To address the urgent need for new therapeutic agents due to treatment failures.

Main Methods:

• Literature review focusing on recent scientific publications.
• Analysis of reported anti-leishmanial activities of heterocyclic compounds.
• Synthesis and evaluation of novel chemical entities against Leishmania.

Main Results:

• Identification of various heterocyclic scaffolds exhibiting significant anti-leishmanial properties.
• Exploration of alternative mechanisms of action beyond current drug targets.
• Demonstration of promising in vitro and in vivo efficacy for selected compounds.

Conclusions:

• Novel heterocyclic compounds represent a promising avenue for developing next-generation anti-leishmanial drugs.
• Overcoming drug resistance requires innovative chemical structures and therapeutic strategies.
• Further research into these heterocycles could lead to effective treatments for leishmaniasis.